[Use of low doses of bromocriptine in chronic schizophrenia resistant to neuroleptics. A preliminary study].
In this work, we report the efficiency of bromocriptine (1.25 and 2.5 mg/day) in 9 neuroleptic resistant chronic schizophrenics. Following an initial four-week placebo period, the subjects successively received bromocriptine (1.25 mg/day), placebo and bromocriptine (2.5 mg/day). The 2 bromocriptine treatments significantly improved the global psychiatric symptomatology and different scores and factors related to the more specific schizophrenic symptomatology. An escape phenomenon seems to occur during the 4th week of the first bromocriptine treatment (1.25 mg/day) but is not observed with the second treatment (2.5 mg/day). All patients improved.
Wolf
M A
MA
Centre hospitalier Douglas, Centre de psychiatrie communautaire, Verdun, Québec, Canada.
Diener
J M
JM
Lajeunesse
C
C
Shriqui
C
C
D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage* / Q000627:therapeutic use; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D010919:Placebos; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D010919:Placebos; D001971:Bromocriptine
Utilisation de faibles posologies de bromocriptine dans la schizophrénie chronique résistante aux neuroleptiques. Une étude préliminaire.